GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » 3-Year EBITDA Growth Rate

Anteris Technologies (Anteris Technologies) 3-Year EBITDA Growth Rate : -22.30% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Anteris Technologies 3-Year EBITDA Growth Rate?

Anteris Technologies's EBITDA per Share for the six months ended in Dec. 2023 was $-1.54.

During the past 3 years, the average EBITDA Per Share Growth Rate was -22.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -6.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 13.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Anteris Technologies was 61.10% per year. The lowest was -62.70% per year. And the median was 13.10% per year.

Competitive Comparison of Anteris Technologies's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, Anteris Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anteris Technologies's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Anteris Technologies's 3-Year EBITDA Growth Rate falls into.


Anteris Technologies 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Anteris Technologies  (OTCPK:AMEUF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Anteris Technologies 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Anteris Technologies's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Anteris Technologies (Anteris Technologies) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anteris Technologies Ltd (OTCPK:AMEUF) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
ASX:4DX ASX:ARX ASX:IPD ASX:EMV ASX:CYC ASX:IMR ASX:NTI ASX:EYE ASX:CVB ASX:MX1 ABT SYK BSX MDT XTER:SHL EW SZSE:300760 DXCM ZBH ALGN
Traded in Other Exchanges
AVR:Australia
Address
Level 3, 9 Sherwood Road, Suite 302, Toowong Tower, Toowong, QLD, AUS, 4066
Website
https://www.anteristech.com
Anteris Technologies Ltd is a structural heart company engaged in delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. The group's solutions include Anteris' DurAVR transcatheter heart valve for younger patients who need a heart valve that will last their lifetime, as well as DurAVR with its biomimetic design that replicates the normal blood flow of a healthy human aortic valve. The company derives key revenue from Australia and the U.S.